本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
New York, London and Tel Aviv - News Direct - 29 November 2022 - Symphony - the leading markets’ infrastructure and technology platform - has acquired Amenity Analytics, a natural language processing (NLP) data analytics solution driving actionable insights to portfolio managers, research professionals, analysts and other financial markets participants. This acquisition will enhance Symphony’s markets strategy with highly relevant data and business insights use cases, including powerful ESG capabilities. Amenity specializes in extracting insights - through research quality assurance, tagging and key drivers - from a variety of content types including earnings call transcripts, news, social media, filings, and research, among other publicly available sources. Through this acquisition, Symphony will provide the market with a purpose-built, transparent and comprehensive insights and analytics offering that will help firms cut through noise and provide business intelligence in real time, reinforcing the company’s position in enabling content distribution. Symphony CEO, Brad Levy, said: “We are excited to provide a highly relevant NLP solution to support firms in addressing some of their most pressing challenges with a powerful business insights platform through the Amenity Analytics acquisition. Our enhanced offering will allow the Symphony community, particularly buy-side firms, to track corporate activity, positioning, messaging, performance and sentiment that can be measured against a peer group. We understand the impact our NLP generated business analytics will have in facilitating insights driven decisions on multiple fronts.” “We are delighted to be joining such a strong team in the industry. This opportunity was uniquely attractive to us as we think the combination of our expertise in NLP with Symphony’s best in class communications platform, will yield exciting outcomes for our customers,” said Nathaniel Storch, Amenity Analytics CEO. “Amenity has developed impactful use cases that tackle real time ESG insights, targeted content delivery and information overload, all key to the future of the finance world, and now they’ll be available to the over 1000 institutions Symphony serves,” he said. Amenity Analytics is the third company Symphony has acquired in the past 18 months. In June 2021, Symphony acquired the trader voice and electronic communication company Cloud9 Technologies and later that year, in August, the counterparty mapping platform StreetLinx. As a result of the integration of both firms’ technology and talent, Symphony has now introduced its Instant Voice proposition and enhanced its directory. Goodwin Procter LLP were legal advisers to Symphony, while D.A. Davidson and Bryan Cave Leighton Paisner LLP were financial and legal advisers, respectively, to Amenity Analytics in this transaction. Financial details of this transaction have not been disclosed. About Symphony Symphony is the most secure and compliant markets’ infrastructure and technology platform, where solutions are built or integrated to standardize, automate and innovate financial services workflows. It is a vibrant community of over half a million financial professionals with a trusted directory and serves over 1000 institutions. Symphony is powering over 2,000 community built applications and bots. For more information, visit www.symphony.com. Hashtag: #SymphonyThe issuer is solely responsible for the content of this announcement.
KUALA LUMPUR, MALAYSIA - Media OutReach - 25 November 2022 - The total Malaysian elderly population is estimated at 2.4 million or 7.5% of the total Malaysian population. According to the Department of Statistics Malaysia (DOSM), ages 60 and above are increasing yearly and Malaysia is set to become a nation of the elderly by 2030, with citizens over 60 reaching 15.3% of the total population. This means 1 out of every 6 people will be over 60 years of age in 8 years' time. (From left) Dr. Lee, Dato' Dr. Rajbans Singh, Lew Mun Yee (President & Founder of AlphaCelle), Chan Suet Fong & Dr. Billy at the pre-launch of AlphaCelle This spells significant threats to Malaysia's health care industry and society in general, and escalates common, degenerative and chronic diseases and immune deficiencies - leading to disability, immobility and dependency and premature deaths amongst Malaysians. In addition, Alzheimer's disease will increase about 50 million people worldwide are Alzheimer's patients. The future treatment for degenerative diseases will not be drugs nor surgeries, but cell therapy . University Kebangsaan Malaysia (UKM) which conducts research into regenerative medicine therapy (RMT) shared that stem cells therapies are a viable avenue to restore organ functions via regeneration and functional repair of damaged tissues. There are two types of human stem cells - Hematopoietic Stem Cells (HSCs), found in cord blood, bone marrow & peripheral blood and Mesenchymal Stem Cells (MSCs), found in Wharton's Jelly of the umbilical cord, bone marrow, fat tissue and tooth pulp. It is the MSCs that are multipotent as they carry and release a wide range of growth factors for repair and rejuvenation of various organ parts. Enters AlphaCelle - the world's first integrated stem cell therapy combining stems cells, high electric potential and exosomes. AlphaCelle sources stem cells ethically from umbilical cords of young and healthy women post-delivery from hospitals, ensuring the highest quality and energy mesenchymal stem cells (MSCs) available. The stem cells are then processed with the most advanced biotechnology under stringent hygienic condition, governed by Current Good Manufacturing Practices (cGMP) compliant by the Malaysian Ministry of Health and the National Pharmaceutical Regulatory Agency (NPRA). Most crucially, the live mesenchymal stem cells have a maximum of 8 hours' time-window from the process of de-thawing from cryo-frozen form to the delivery of it intravenously that ensure maintaining the continuous living nature and quality of the MSCs. Also, AlphaCelle uses a high volume of passage 2 MSCs, which are of the highest quality. Mr Lew Mun Yee, President & Founder of AlphaCelle shares that stem cells therapy increases in efficacy when combined with high-electric potential therapy as it purifies the blood and enhances its circulation in the body which then optimises the dissemination of stem cells. The high electric potential medical device promotes better sleep quality and enhances blood circulation hence allowing the MSCs to reach the required area of the body to regenerate and repair weak and damaged cells. AlphaCelle's brand promise is "Life Anew", suggesting with regenerative medicine, everyone's lives can be restarted, youthful and away from pain. Its mission is to capitalize stem cell therapy for every Malaysian. In short, AlphaCelle aims to help delay aging, reduce diseases so Malaysians can live fulfilling live into their golden years with dignity. AlphaCelle recently conducted rolled out public education workshops with their panel of medical practitioners to discuss the future of regenerative therapies. Dr Lee Tjen Jhung, Cardiologist at the National Heart Institute (IJN) of Malaysia shared that 15% of the deaths in Malaysia is caused by heart disease - the number 1 killer in the nation and globally. "While heart diseases are usually treated with medication, angioplasty and by-pass surgery, cell-based regenerative therapy is gaining popularity in the cardiovascular field due to the ability of MSCs to promote new tube formation of ECs to provide new blood for ischemic tissue and promoting the formation of new blood vessels," said Dr Lee. Dato' Dr Rajbans Singh, Consultant Physician and Geriatrician, President of the Malaysian Wellness Society, with years of aging research and clinical studies, said stem cells are crucial to treating aging. "At birth, the human body has approximately 80 million active stem cells working and by age 40, less than 25 million active stem cells are working. Aging leads to a massive loss of stem cells in the body where organs and tissues become unable to repair and regenerate hence the body gradually ages and deteriorates," he said. Dr Billy Lee, an expert in stem cell therapy, studies its efficacy as regenerative and anti-aging medicine. The MSCs collected at the centre are utilized to potentially treat OR to improve including orthopaedic injuries, brain trauma, cardiovascular diseases, metabolic diseases, joints degeneration and neurodegenerative diseases. "For comprehensive regenerative treatment, the benefits we reap from stem cell therapy would be exponentially increased with the addition of exosomes and high electric potential. Exosomes contain many growth factors and cytokines which act as 'boosters' to promote more MSC activity, hence prolonging and maximizing MSCs effects." said Dr Lee. For more information, please visit www.alphacelle.com and facebook.com/AlphaCelle Hashtag: #AlphacelleThe issuer is solely responsible for the content of this announcement.
Zapp’s First Product, the i300 Performance City Bike, with its Carbon Composite Body, Delivers Premium Performance Capabilities to Urban Mobility Riders Unique Charging Solution with Ultra-Lightweight (6kg) Portable Battery Pack that can be Charged via any Standard 220v/110v Wall Socket Innovative Exoskeleton Architecture Integrates Zapp’s Design DNA, Provides Superior Performance Relative to Powered Two-Wheeler (“P2W”) Peers, Reduces Overall Components and Simplifies Manufacturing Assembly Strategic Manufacturing Partnership with Summit Group Already in Place and at Start of Production Asset-Light, Capital Efficient Business Model Aims to Achieve Near-Term Positive Free Cash Flow Estimated Post-Transaction Enterprise Value of $573 Million with up to $274 Million in Net Cash to Fund Growth Assuming No Redemptions by CIIG II stockholders; No Minimum Cash Condition NEW YORK and LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CIIG Capital Partners II, Inc. (Nasdaq: CIIG) (“CIIG II”), a U.S. publicly-listed blank check company, and Zapp Electric Vehicles Limited (“Zapp” or the “Company”), a UK-based, high-performance two-wheel electric vehicle company, have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company, Zapp Electric Vehicles Group Limited, a Cayman Islands exempted company, is expected to list its ordinary shares on the Nasdaq under the ticker symbol “ZAPP”. Zapp was founded in 2017 by a group of mobility experts with a vision and commitment to bring high-performance to urban mobility through original, advanced design with an emphasis on safety, quality, customer experience and full-cycle sustainability. Zapp’s first product to enter the market, the i300, has received widespread acclaim and consumer interest for its embodiment of these values. Unlike other urban electric bikes, the i300 is built around an innovative exoskeleton architecture and is powered by an advanced British-designed electric motor, which enables it to match the acceleration of high-performance motorcycles in a step-through architecture. A lightweight alloy and composite bodywork allow for a slim total weight of just 108 kg (without battery packs). The i300’s interior permanent magnet electric motor and carbon fiber belt drive combine to drive acceleration from 0 to 30 mph (48km/h) in just 2.3 seconds and from 0 to 60 mph (97km/h) in 5.0 seconds. The i300 utilizes ultra-portable lithium-ion battery packs weighing just 6 kg each. The battery packs can be charged from 20% to 80% via standard 220v/110v wall sockets in under 40 minutes. The portability of the battery packs makes the i300 easy to charge anywhere and at any time without reliance on a public charging network. The i300 is well-positioned to handle the average daily commute for urban drivers. Zapp expects to implement a high-quality direct-to-customer experience called DSDTC (drop-ship-direct-to-customer). Once a customer places an online order, their selected model will be processed and conveniently delivered directly to their home by “Zappers,” who are independent service agents who perform deliveries in dedicated and purpose-designed plug-in hybrid service vans. Zappers also provide at-home inspection, service and support throughout the life of the vehicle. As part of Zapp’s full-stack e-commerce platform, customers are expected to have access to highly competitive leasing and insurance solutions. Zapp also uses a Gen-2 sustainability design approach that requires fewer components and assembly steps and bodywork made from composites with green-to-make materials, with substantially all components being recyclable (or in the case of the battery packs, refurbished for a second use at end-of-life). Zapp Investment Highlights Large and Growing ~$130bn1 Global P2W Market: Strong organic and replacement demand for electrification in largely underpenetrated EV two-wheeler market provides an attractive opportunity for Zapp. Innovator in High-Value EV “Urban Motorcycle” Category: Zapp is maximizing the benefits of EV technology through its creation of a new P2W category enabled by its ground-up design for an original and all-new vehicle architecture. Portable and Powerful Battery Pack Technology: Zapp’s differentiated approach to battery packs addresses concerns with range anxiety and charging networks as its removable light weight battery packs can be charged via any standard 220v/110v wall sockets. Highly Innovative Exoskeleton Architecture: Zapp’s innovative exoskeleton architecture lowers weight and creates simplified, efficient and low-cost assembly. Low Capital Requirements Aiming to Achieve Near-Term Positive Free Cash Flow: Zapp has strategic partnerships with major Asian contract manufacturer Summit Group and receivables financing provider EXIM Bank. Diversified and Experienced Management: The management team brings together proven entrepreneurs and professionals with deep domain expertise and thought leadership. “Entering the public markets is an important milestone for Zapp and one we have been diligently working toward since our founding,” said Swin Chatsuwan, Founder and Chief Executive Officer of Zapp. “Combining with CIIG II and becoming a publicly listed company will enable us to scale our business, increase production and fulfill demand for electrification in the largely underpenetrated electric two-wheel market.” Gavin Cuneo, CIIG II Co-Chief Executive Officer, added: “The two-wheel category is large, growing and highly fragmented. As the world quickly moves toward electric mobility, we expect this segment will be a leader globally. We believe Zapp’s combination of high design with high performance will allow them to capture share and take advantage of this momentum. We look forward to completing our business combination and working with Zapp’s world-class team to help accelerate their mission to revolutionize electric mobility.” Transaction Overview The combined company will have an estimated fully-diluted post-transaction enterprise value of $573 million, consisting of an estimated equity value of $852 million, $274 million in new cash to the balance sheet (assuming no redemptions by CIIG II public stockholders), and $5 million in existing cash2. Cash proceeds raised will consist of CIIG II’s approximately $294 million cash in trust, net of redemptions. With no minimum cash condition, the cash in the CIIG II trust account is anticipated to support the Company’s growth capital needs, including Zapp’s production, marketing and sales efforts. It is intended that 100% of existing Zapp shareholders will roll over their equity and, assuming no redemptions and full rollover, own approximately 59% of the pro forma equity of the combined company in connection with the transaction. The business combination has been approved by the boards of directors of both Zapp and CIIG II and is expected to close in the first half of 2023, subject to stockholder approvals and other customary closing conditions. For a summary of the material terms of the proposed transaction, as well as a supplemental investor presentation, please see the Current Report on Form 8-K filed today with the U.S. Securities and Exchange Commission (the “SEC”). Additional information about the proposed transaction will be described in CIIG II’s proxy statement relating to the business combination, which it will file with the SEC. Advisors SPAC Advisory Partners, a division of Kingswood Capital Partners, is serving as exclusive financial advisor to Zapp Electric Vehicles. Latham & Watkins LLP is serving as legal advisor to Zapp Electric Vehicles. Weil Gotshal & Manges LLP, and Orrick, Herrington & Sutcliffe LLP are serving as legal advisors to CIIG Capital Partners II. Gateway Group is serving as Global Investor Relations Advisor and Media Relations for North America. Influence Mobility is serving as Global Media Relations for Zapp Electric Vehicles. Further Information On The Transaction For further information on the proposed transaction, please visit ciigpartners.com or the investor section of zappev.com. About CIIG Capital Partners II, Inc CIIG Capital Partners II, Inc. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. CIIG II’s units, Class A common stock and warrants trade on the Nasdaq under the ticker symbols “CIIGU,” “CIIG,” and “CIIGW” respectively. About Zapp Zapp Electric Vehicles Limited is a British company – run by a team of experts from the mobility industry – on a mission to redefine the electric two-wheeler segment. Launching its debut product in June 2022, Zapp created the i300 as an urban electric high-performance two-wheeler capable of traditional motorcycle levels of performance in a step-through format, combining ease of use with exhilaration and fun. The i300 is the first in a suite of high-performance electric two-wheelers expected to come to market from Zapp. Zapp is expected to operate a high-quality direct-to-customer (DTC) experience called DSDTC (drop-ship-direct-to-customer). Customers ordering the i300 online will have their bikes conveniently delivered to their home by “Zappers” who provide at-home inspection, service and support throughout the vehicle ownership lifecycle. Investor Relations Contact: Gateway Investor Relations Cody Slach, Ralf Esper (949) 574-3860 zapp@gatewayir.com North America Media Relations Contact: Gateway PR Zach Kadletz (949) 574-3860 zapp@gatewayir.com Global Media Relations Contact: Influence Nick Francis +44 7767615115 pr@zappev.com Forward-Looking Statements This document contains certain forward-looking statements within the meaning of U.S. federal securities laws with respect to the proposed business combination (the “Business Combination”) between Zapp, CIIG II and Zapp Electric Vehicles Group Limited (“PubCo”), including statements regarding the benefits of the transaction, the anticipated timing of the transaction, the anticipated growth in the industry in which Zapp operates and anticipated growth in demand for Zapp’s products, projections of Zapp’s future financial results and possible growth opportunities for Zapp. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “budget,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of CIIG II’s securities, (ii) the risk that the transaction may not be completed by CIIG II’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by CIIG II, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the business combination agreement by the stockholders of CIIG II, (iv) the lack of a third party valuation in determining whether or not to pursue the proposed Business Combination, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement, (vi) the effect of the announcement or pendency of the transaction on Zapp’s business relationships, performance, and business generally, (vii) risks that the proposed Business Combination disrupts current plans of Zapp or diverts management’s attention from Zapp’s ongoing business operations and potential difficulties in Zapp’s employee retention as a result of the proposed Business Combination, (viii) the outcome of any legal proceedings that may be instituted against Zapp, PubCo, CIIG II or their respective directors or officers related to the proposed Business Combination, (ix) the ability of PubCo, CIIG II or a successor thereto to maintain the listing of its securities on The Nasdaq Stock Market LLC, (x) volatility in the price of the securities of PubCo, CIIG II or a successor thereto due to a variety of factors, including changes in the competitive and highly regulated industries in which Zapp plans to operate, variations in performance across competitors, changes in laws and regulations affecting Zapp’s business and changes in the combined capital structure, (xi) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed Business Combination, and identify and realize additional opportunities, (xii) the risk of downturns in the highly competitive electric vehicle industry, (xiii) the ability of Zapp to build the Zapp brand and consumers’ recognition, acceptance and adoption of the Zapp brand, (xiv) the risk that Zapp may be unable to develop and manufacture electric vehicles of sufficient quality and on schedule and scale, that would appeal to a large customer base, (xv) the risk that Zapp has a limited operating history, has not yet released a commercially available electric vehicle and does not have experience manufacturing or selling a commercial product at scale and (xvi) the risk that Zapp may not be able to effectively manage its growth, including its design, research, development and maintenance capabilities. The foregoing list of factors is not exhaustive. Forward-looking statements are not guarantees of future performance. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of PubCo’s registration statement on Form F-4, the proxy statement/prospectus discussed below, CIIG II’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q and other documents filed by PubCo, CIIG II or a successor thereto from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. The forward-looking statements in this document represent the views of PubCo and CIIG II and Zapp as of the date of this document. Subsequent events and developments may cause that view to change. Readers are cautioned not to put undue reliance on forward-looking statements, and all forward-looking statements in this document are qualified by these cautionary statements. Zapp, PubCo and CIIG II assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. None of Zapp, PubCo nor CIIG II gives any assurance that Zapp, PubCo or CIIG II will achieve its expectations. The inclusion of any statement in this document does not constitute an admission by Zapp, PubCo or CIIG II or any other person that the events or circumstances described in such statement are material. Additional Information and Where to Find It This document relates to the proposed Business Combination between CIIG II, Pubco and Zapp. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act. In connection with the Business Combination, PubCo intends to file a registration statement on Form F-4 (as may be amended from time to time, the “Registration Statement”) including a preliminary proxy statement of CIIG II and a preliminary prospectus of PubCo, and after the Registration Statement is declared effective, CIIG II will mail a definitive proxy statement relating to the Business Combination to CIIG II’s stockholders. The Registration Statement, including the proxy statement/prospectus contained therein, when declared effective by the SEC, will contain important information about the Business Combination and the other matters to be voted upon at a meeting of CIIG II’s stockholders to be held to approve the Business Combination (and related matters). PubCo and CIIG II may also file other documents with the SEC regarding the Business Combination. CIIG II stockholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the Business Combination, as these materials will contain important information about Zapp, PubCo, CIIG II and the Business Combination. When available, the definitive proxy statement and other relevant materials for the Business Combination will be mailed to CIIG II stockholders as of a record date to be established for voting on the Business Combination. Stockholders will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement and other documents filed or that will be filed with the SEC by CIIG II through the website maintained by the SEC at www.sec.gov, from CIIG II’s website at https://ciigpartners.com/ or by written request to CIIG II at 40 West 57th Street, 29th Floor, New York, New York 10019. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. Participants in the Solicitation CIIG II, Pubco and Zapp and their respective directors and officers may be deemed to be participants in the solicitation of proxies from CIIG II’s stockholders in connection with the proposed Business Combination. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of CIIG II’s stockholders in connection with the proposed transactions will be set forth in the proxy statement/prospectus when it is filed with the SEC. You can find more information about CIIG II’s directors and executive officers in CIIG II’s final prospectus filed with the SEC on September 14, 2021. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed Business Combination may be obtained by reading the proxy statement/prospectus regarding the proposed Business Combination when it becomes available. You may obtain free copies of these documents as described in the preceding section. No Offer or Solicitation This document is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of PubCo, Zapp, CIIG II or any of their respective affiliates. No such offering of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the Securities Act, or an exemption therefrom. The contents of this document have not been reviewed by any regulatory authority in any jurisdiction. ____________________________ 1Source: Fortune Business Insights. TAM figure includes internal combustion engine vehicles and represent 2022 figures. 2 Projected balance as of February 2023
Jeito Capital co-leads oversubscribed EUR 50 million Series C financing with Brandon Capital CatalYm is developing a new class of anti-cancer immunotherapies, which have already demonstrated initial promising clinical results in advanced-stage solid tumor patients Jeito Capital strengthens its strong and diversified portfolio with first German investment Paris, France, November 22nd 2022 - Jeito Capital ("Jeito"), a leading independent international private equity firm dedicated to healthcare and biopharma, announced today that it has co-led a EUR 50 million Series C financing round in CatalYm, a clinical-stage biopharmaceutical company developing novel immunotherapies to fight cancer. The oversubscribed financing was co-led by Brandon Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures, and Coparion. CatalYm was founded in 2016 as a spin-off from Würzburg University and is based in Munich (Germany). CatalYM’s lead candidate, visugromab is a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). It is currently in Phase 2 clinical studies in patients with solid tumors that are relapsed/refractory to prior anti-PD1/-PD-L1 treatment. GDF-15 acts as a key regulator of immune cell activation and as an inhibitor of immune cell infiltration into the tumor tissue. Proceeds from the financing will primarily be used to expand the Phase 2 clinical development program of visugromab. This expansion is based on convincing efficacy and durability results in advanced, last-line patients in Phase 1 and continued positive clinical responses in the ongoing GDFATHER-2 trial (GDF-15 Antibody-mediaTed Human Effector cell Relocation Phase 2). The expanded Phase 2 clinical studies will enroll patients at clinical centers in Europe and the United States. Jeito selected CatalYm in line with its investment strategy to support the development of the most promising European Biopharma with growth and acceleration potential. Dr. Andreas Wallnoefer, Partner at Jeito Capital will join CatalYM’s Board of Directors. Throughout 2022, Jeito has continued to build a portfolio of innovative companies across diverse therapeutic areas and across stages of development with the strong potential to improve the lives of patients. With CatalYm, Jeito makes its first investment in Germany, which has a very dynamic and internationally recognized biopharma ecosystem. Jeito closed its Jeito I fund at €534 million in September 2021 and has to date invested in high-quality biopharma companies with the potential to become market leaders in France, Belgium, Denmark, Switzerland, the UK and the US. Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito, commented: “We are thrilled to co-lead this new round of financing in CatalYm to further accelerate its clinical development and support its world leading research for the benefit of severely ill patients with no satisfying therapeutic solution. Jeito is committed to supporting and accelerating the development of the most promising European biopharma companies. CatalYm has the potential of growth and acceleration for patients, which is a core value for Jeito. Jeito selected this clinical stage company that has a promising new therapy approach to treat cancer, which has already demonstrated the first clinical signs of activity for severe relapsed patients. We look forward to working with the experienced CatalYm team.” Dr. Andreas Wallnoefer, Partner at Jeito, added: “Visugromab has shown promising results in enhancing the immune response to fight cancer in its first clinical trials, resulting in several impressive responses in patients with advanced tumors and last line treatments. The drug has great potential to improve patients’ lives and become part of cancer immune therapy regimens given its important efficacy profile and good tolerability.” Dr. Phil L’Huillier, Chief Executive Officer at CatalYm, concluded: “The success of our Series C financing, based on strong clinical data, is a further validation that visugromab is emerging as a new anti-cancer immunotherapeutic drug with the potential to transform the immuno-oncology landscape. We deeply value the commitment of our new and existing investors, which will enable further clinical development moving our lead program towards pivotal studies.” About Jeito Capital Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States. @Jeito_lifeLinkedInFor more information, please visit www.jeito.life, or follow @Jeito_life on Twitter or LinkedIn. About CatalYm CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment. We are pioneering the reversal of GDF-15-mediated immunosuppression to induce a potent antitumoral immune reaction in non-responsive tumors. CatalYm’s lead program visugromab is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications which will expand the treatment horizon for current and future immunotherapies. About visugromab (CTL-002) Visugromab, formerly known as CTL-002, is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). GDF-15 secretion by the tumor has been shown to prevent T cell migration into the tumor and suppresses T cell function and the adaptive immune response in the tumor microenvironment. This enables the tumor to evade the immune system and become resistant to standard of care and current immunotherapy approaches such as checkpoint inhibitors. Visugromab counteracts these immuno-suppressive mechanisms by neutralizing GDF-15, enhancing the infiltration of immune cells into the tumor, improving both priming of T cells by dendritic cells and tumor killing by T cells and NK cells. For further information please contact: Jeito Capital Rafaèle Tordjman Assia Mouhout, EA assia@jeito.life Tel : +33 6 76 49 37 94 Consilium Strategic Communications Mary-Jane Elliott / Davide Salvi / Kris Lam Jeito@consilium-comms.com Tel: +44 (0) 20 3709 5700 Marion Bougeard marion@achto-conseil.fr Tel : +33 6 76 73 57 31 CatalYm GmbH Dr. Phil L’Huillier, CEO info@catalym.com Trophic Communications Dr. Stephanie May Phone: +49 171 185 56 82 catalym@trophic.eu
SINGAPORE - Media OutReach - 18 November 2022 - After years of design and development, SocialFi's blockchain protocol e-commerce platform Easy Buy is finally ready to be officially launched. Create an online digital economic ecological agreement and an encrypted asset value investment portal. The blockchain protocol independently developed by Easy Buy creates more practical functions for APP applications, such as realizing safe and efficient clearing and payment systems, supply chain logistics, SocialFi, product traceability, The construction of automatic execution of smart contracts, etc. Easy Buy was established in Singapore. It is an emerging WEB3.0 streaming media e-commerce aggregation platform. Storage + Ecological Supply Chain". In Easy Buy's extensive application ecology, the SocialFi sector is a very important ecology. The Easy Buy community takes the decentralization of values as the core of the community as the main ideology of the community, and will be committed to "decentralization" and autonomy. Ways to build a diversified DAO community. All benefits of a community are shared by community members. Based on WEB3.0, Easy Buy will realize the combination of cultural creativity and financial world, and will generate huge value, and will also lead human beings into various virtual world civilizations. Easy Buy—SocialFi plate application Easy Buy is a high-performance chain group that can realize the interoperability of EVM multi-chain contracts. The Web3.0 aggregation platform Easy Buy will serve all entrepreneurs, consumers and merchants who want to explore the blockchain world in the future. About Easy Buy The future development of the SocialFi sector is as follows: 1. Social To Earn (connection monetization), core function realization subject: Easy Buy--promote sharing--get rewards--precipitate traffic---users complete corresponding tasks---Social To Earn 2. Chat function (add friends, transfer money, send red envelopes) Easy Buy user registration --- form your own unique NFT "business card" --- scan online or enter your account number to add friends --- send messages --- send digital asset red envelopes --- open multi-chain bridge --- support multiple The digital assets on the public chain are traded/transferred/entered into the wallet in Easy Buy 3. Encrypted chat, burn after reading Easy Buy users can set the encrypted chat mode----Easy Buy smart contract is automatically executed---package the chat data into blocks---the user chooses the package data---generate the secret key---give it to the user Easy Buy users adopt the seamless chat mode --- Automatic execution of Easy Buy smart contracts --- Data are automatically packaged into blocks --- Generate execution commands --- Users choose to execute smart contracts --- Data into the black hole address --- --Burn after reading. Easy Buy is committed to providing users with a more open and rich social experience, advocating the realization of social value, matching users who are compatible with each other through precise algorithms, and encouraging users to break the boundaries of the real world, through "discovery", "roaming" " and other functions to become friends with people all over the world. Easy Buy's social value based on the underlying structure of SocialFi is the natural soil for the concept of blockchain decentralized autonomy. After several months of trying to use blockchain technology to solve privacy data security, community incentives and other issues, Easy Buy's user privacy Safety, community activity and atmosphere have been significantly improved and optimized. Embrace the use of blockchain technology to reconstruct the next-generation decentralized value social network platform, so that data privacy and security, and the value of digital assets can return to individuals. Hashtag: #EasyBuyThe issuer is solely responsible for the content of this announcement.
Optimizing Supply Chain Payments Via Virtual Cards & Enhanced ACH Creates Significant Cost-Efficiency, Workflow Automation, & Payment Fraud Risk Reduction for Enterprise Clients BOSTON, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Today, enterprise B2B payments leader Treasury Intelligence Solutions (TIS) announced the launch of a new domestic payment orchestration program. Using the program, enterprises operating in certain localities, such as the U.S., can leverage TIS to simplify and streamline payment activity across their domestic network of suppliers, vendors, and partners. By analyzing each unique vendor relationship and supplier network, TIS can determine which domestic payment option provides the greatest financial and operational efficiency across ACH, virtual card, check, or wire. Then, TIS provides a streamlined and highly secure channel for enterprises to execute these transactions via integrations with several selected institutional and fintech partners. Payments that are channeled through this workflow are ultimately rewarded through a rebate program that can provide significant savings for companies with high payment volumes. For added simplicity and security, enterprises that join the program can submit a single payment instruction file to TIS for identifying the relevant payees, invoices, execution dates, and eligible payment options. This drastically streamlines the process for companies to submit payment instructions through their back-office and eliminates the need to store redundant supplier payment data in their originating system, such as an ERP. It also significantly reduces the risk of payment fraud via an enhanced segregation of duties workflow for managing supplier payment master data. Having initially introduced the program to the U.S. in July 2022, there are already more than 75,000 suppliers enrolled, and over $20 billion in applicable payments are being routed through TIS annually. According to Chris Calhoun, CEO Americas at TIS, "Optimizing the use of local payment modalities in the U.S. and in other regions allows our clients to simplify and streamline their supply chain payments and achieve a material financial benefit. As such, developing solutions that provide efficiency and risk reduction in these areas continues to be a top priority." For more information about this announcement, refer to the below contact information or download the expanded factsheet. Contact Information: Jennifer Knutel VP Marketing jennifer.knutel@tispayments.com 978-875-2085 Related Images Image 1
A12 藝術空間
activity
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
